HemOnc Today

CURRENTLY VIEWING:

The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents
Commentary

Completion lymph node dissection ‘not yet obsolete’

Vernon K. Sondak, MD

Bristol-Myers Squibb, Clovis Oncology to evaluate nivolumab-rucaparib combination

National Comprehensive Cancer Network appoints bladder cancer panel chairman

Be The Match appoints CEO

Pembrolizumab fails to improve survival in head and neck squamous cell carcinoma

Physician joins New York Cancer & Blood Specialists

Prostate Cancer Foundation announces award recipients

The University of Texas MD Anderson Cancer Center named best cancer hospital in nation

ASCO presents value-based solutions to promote affordability, preserve innovation of cancer drugs

Telephone-based intervention after lung cancer screening quadruples smoking cessation rates

Society of Interventional Oncology elects officers, appoints board members

Atlantic Health System Cancer Care appoints chief of hematology, oncology

Cover Story

Success of abiraterone trials prompts ‘mind shift’ in prostate cancer treatment

Editorial

The pathway to value: A complicated journey begins with one step

John Sweetenham, MD

FDA News

FDA allows marketing of test to help detect blood cancers

FDA approves Vectibix for RAS wild-type metastatic colorectal cancer

FDA approves Idhifa for IDH2-mutated acute myeloid leukemia

FDA clears expansion of cooling cap to reduce hair loss in patients with solid tumors

FDA approves Nerlynx for adjuvant treatment of HER-2-positive breast cancer

FDA expands indication of Yervoy to include pediatric patients with melanoma

In the Journals Plus

Genetic profiling feasible, useful in pediatric brain tumors

Sorafenib benefit dependent on hepatitis status in patients with HCC

Opioid use common among cancer survivors

Standard surgery for melanoma with sentinel-node metastases does not extend survival

Selumetinib fails to improve PFS in KRAS–mutant advanced NSCLC

Idarubicin dose escalation increases leukemia-free survival in AML

Nivolumab, ipilimumab combination shows promise for renal cell carcinoma

Reversion mutations may predict chemotherapy response in recurrent serous ovarian cancer

Radiotherapy boost may reduce ipsilateral breast tumor recurrence in women with DCIS

Biomarkers may guide personalized therapy for castration-resistant prostate cancer

Definitions of clinical benefit differ between oncology society frameworks

Adjuvant chemoradiotherapy improves survival in nasopharyngeal carcinoma

ASCO issues recommendations on second-line hormonal therapy for castration-resistant prostate cancer

Experimental targeted therapy improves survival in acute myeloid leukemia

FDA boxed warning reduces erythropoietin-stimulating agent use

Emicizumab prophylaxis lowers bleeding rate in hemophilia A

Point/Counter

Should oncologists recommend hormone therapy plus abiraterone for patients with nonmetastatic prostate cancer?

Advertisement
Advertisement